In principle, low molecular weight compounds could be used as alternatives to antibodies for tumor targeting applications. Our proprietary DNA-Encoded Chemical Libraries greatly facilitate the hit discovery process from millions of molecules. In analogy to Antibody-Drug Conjugates (ADCs), Small Molecule-Drug Conjugates (SMDCs) feature cytotoxic drugs and other payloads which are selectively guided to the disease site by small molecule ligands.
SMALL MOLECULE-DRUG CONJUGATES At Philogen we have identified and patented a number of pathology-associated targets, their corresponding ligands and appropriate linkers for the development of SMDCs.
Cazzamalli (2016) Mol. Cancer Ther. DOI: 10.1158/1535-7163.MCT-16-0283;
Casi & Neri (2015) J Med Chem. 58:8751-61 Review;
Krall et al. (2014) Angew. Chem. Int. Ed. 53:4231-5;
Krall et al. (2014) Chem. Sci. 5:3640-4;
Krall et al. (2013) Angew Chem Int Ed Engl. 52:1384-402 Review;
Müller et al. (2013) J Nucl Med. 54:124-31;
Ahlskog et al. (2009) Bioorg. Med. Chem. Lett. 19:4581-6;
Dumelin et al. (2008) Angew Chem Int Ed Engl. 47:3196-201